Trial Set for Gut Infection Biologic Treatment

by admin | Apr 18, 2022 | Press Release

Read more

Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection

by admin | Apr 15, 2022 | Press Release

— FDA clearance of investigational new drug (IND) application — Initiation of multisite Phase 2 study in spring 2022 — Phase 1 pharmacokinetic study completed Seattle, WA, April 18, 2022 – Lumen Bioscience, a clinical-stage biotechnology company developing biologic...

Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics

by admin | Apr 7, 2022 | Press Release

Read more

A spirulina-based biomanufacturing platform

by admin | Apr 6, 2022 | Press Release

Read more

KYORIN and Lumen Bioscience Reach Collaboration Research Agreement

by admin | Mar 30, 2022 | Press Release

Read more